Online inquiry

IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7919MR)

This product GTTS-WQ7919MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7919MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14987MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ8173MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ12795MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ8639MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ14556MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ3458MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ14835MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ11759MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW